Clinical Trial Update: CEP-701 (Lestaurtinib) in Myelofibrosis [Phase 1, Phase 2]

View source ↗

Summary

Clinical trial update on CEP-701 (lestaurtinib) in myelofibrosis, with additional conditions essential thrombocythemia and polycythemia vera; current status is …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Essential Thrombocythemia
• Myelofibrosis
• Polycythemia Vera

Drugs mentioned

• CEP-701 (Lestaurtinib) (lestaurtinib)

Snippet

Sponsor: Ronald Hoffman | Conditions: Myelofibrosis, Essential Thrombocythemia | Phase 1, Phase 2 | Status: UNKNOWN